New targeted therapy for advanced melanoma associated with 80 percent response rate

A multicentre study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumour shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Centre and colleagues at other cancer centres have published their findings in the August 26 edition of the New England Journal of Medicine...

Read the whole article on

More from